Fennec Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Fennec Pharmaceuticals

11/11/2022 12:48

* Fennec Pharmaceuticals Inc  FENC.OQ  reported a quarterly
adjusted loss of 31 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 18 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Fennec Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 31 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Fennec Pharmaceuticals Inc shares had risen by 1.0% this
quarter and gained 85.9% so far this year.
    * The company reported a quarterly loss of $8.09 million.
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
11 at 12:48 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.18          -0.31          Missed
 Jun. 30 2022      -0.14          -0.19          Missed
 Mar. 31 2022      -0.14          -0.14          Met
 Dec. 31 2021      0.75           -0.18          Missed